Showing 7851-7860 of 8720 results for "".
- Asana BioSciences’ JAK/SYK Inhibitor Performs Well in Phase 2b Study of Hand Eczemahttps://practicaldermatology.com/news/asana-biosciences-jaksyk-inhibitor-performs-well-in-phase-2b-study-of-hand-eczema/2460409/Asana BioSciences’ investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) showed rapid and significant improvement in a phase 2b study of 97 adult patients with moderate-to-severe chronic hand eczema. The study was a randomiz
- Zilxi Approved: First Topical Minocycline Treatment for Rosaceahttps://practicaldermatology.com/news/zilxi-approved-first-topical-minocycline-treatment-for-rosacea/2460408/The FDA has approved Zilxi™ (minocycline) topical foam, 1.5%, from Menlo Therapeutics for the treatment of inflammatory lesions of rosacea in adults. Zilxi, developed as FMX103 by Menlo’s wholly-owned subsidiary Foamix Pharmaceuticals Ltd., is the first minocycline product of any kind
- Cynosure Rolls Out Elite iQ Aesthetic Workstation For Laser Hair Removal, Skin Revitalizationhttps://practicaldermatology.com/news/cynosure-rolls-out-elite-iq-aesthetic-workstation-for-laser-hair-removal-skin-revitalization/2460407/
- Promising Data from Dermavant's Phase 2b Study of Tapinarof in Psoriasishttps://practicaldermatology.com/news/promising-data-from-dermavants-phase-2b-study-of-tapinorof-in-psoriasis/2460405/Patients treated with once daily tapinarof 1% demonstrated improvement in PASI75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase
- Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for ADhttps://practicaldermatology.com/news/arena-completes-full-enrollment-of-etrasimod-phase-2-advise-trial-for-ad/2460403/
- AAD: Sixty Percent of Americans Have Gotten Sunburned So Badly Their Clothes Were Uncomfortablehttps://practicaldermatology.com/news/aad-sixty-percent-of-americans-have-gotten-sunburned-so-badly-their-clothes-were-uncomfortable/2460396/Most Americans say they have gotten a sunburn and admit it has impacted their day-to-day life, according to a recent AAD survey. Of those who have been sunburned, 60 percent said their sunburns made their clothes uncomfortable; 43 percent said they couldn’t sleep; and 21 percent said they w
- Done Deal: AbbVie Completes Acquisition of Allerganhttps://practicaldermatology.com/news/done-deal-abbvie-completes-acquisition-of-allergan/2460389/AbbVie completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court. In connection with the closing of the transaction, the AbbVie Board of Directors has elec
- Industry Responds to COVID-19: Allergan Foundation Doubles Down on COVID-19 Donationshttps://practicaldermatology.com/news/industry-responds-allergan-foundation-doubles-down-on-covid-19-donations/2460385/The Allergan Foundation fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic, doubling their COVID-19 donations to date, raising the total to $4 million. The donations are dedicated to 57 organ
- Survey: Social Media Isn’t All That Helpful for Growing Your Derm Practicehttps://practicaldermatology.com/news/survey-social-media-isnt-all-that-helpful-for-growing-your-derm-practice/2460384/Patients often do not take social media into consideration when looking for a dermatologist, according to a survey from researchers at the George Washington University. The survey appears in the Journal of Drugs in Derma
- Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of mPVhttps://practicaldermatology.com/news/cabaletta-bio-receives-fda-fast-track-designation-for-dsg3-caart-for-the-treatment-of-mpv/2460383/The U.S. Food and Drug Administration (FDA) granted Cabaletta Bio’s DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells) Fast Track Designation for improving healing of mucosal blisters in patients with mPV. DSG3-CAART is designed to specifically target the cause of mP